ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,460.48
-0.41%
US Tech 100
19,181.60
-0.43%
Dow Jones
39,118.86
-0.12%
Brent Oil
84.85
0.00%
Bitcoin
61,570.34
1.12%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Sanofi (SAN)

  7. Sanofi (SAN) News

SAN

Sanofi (SAN)

Sanofi
Date:
Sort by:
 Showing the most relevant articles for your search:EU:SAN
DateTimeSourceHeadlineSymbolCompany
02/16/20241:00AMGlobeNewswire Inc.Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)EU:SANSanofi
02/15/20248:00AMGlobeNewswire Inc.Communiqué de presse : Des données de phase II publiées dans le NEJM illustrent le fort potentiel d’efficacité du frexalimab dans le traitement de la sclérose en plaques récurrente-rémittenteEU:SANSanofi
02/15/20248:00AMGlobeNewswire Inc.Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSEU:SANSanofi
02/15/20248:00AMGlobeNewswire Inc.Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSEU:SANSanofi
02/05/20242:00AMGlobeNewswire Inc.Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnessesEU:SANSanofi
02/05/20242:00AMGlobeNewswire Inc.Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnessesEU:SANSanofi
02/05/20242:00AMGlobeNewswire Inc.Communiqué de presse : Entraide, conditions de travail flexibles, salaire pendant un an : Sanofi lance un programme mondial pour les employés touchés par un cancer ou une maladie graveEU:SANSanofi
02/01/20241:30AMGlobeNewswire Inc.Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology PipelineEU:SANSanofi
02/01/20241:30AMGlobeNewswire Inc.Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology PipelineEU:SANSanofi
02/01/20241:30AMGlobeNewswire Inc.Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive CommitteeEU:SANSanofi
02/01/20241:30AMGlobeNewswire Inc.Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive CommitteeEU:SANSanofi
02/01/20241:30AMGlobeNewswire Inc.Communique de presse - 2023 : Croissance des ventes et du bénéfice net par action à TCC, succès des lancements de produits et avancée du portefeuille R&D en ImmunologieEU:SANSanofi
02/01/20241:30AMGlobeNewswire Inc.Communiqué de presse : François-Xavier Roger nommé Directeur Financier, membre du Comité exécutif de SanofiEU:SANSanofi
01/25/20242:30PMGlobeNewswire Inc.Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)EU:SANSanofi
01/25/20242:30PMGlobeNewswire Inc.Communiqué de presse : Dupixent® : premier et seul médicament approuvé par la FDA pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 moisEU:SANSanofi
01/25/20242:30PMGlobeNewswire Inc.Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)EU:SANSanofi
01/23/20246:05AMDow Jones NewsSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateEU:SANSanofi
01/23/20245:02AMDow Jones NewsECHO BOURSE: L'acquisition d'Inhibrx par Sanofi est logique - CitiEU:SANSanofi
01/23/20244:53AMMF Dow Jones (Italiano)Acquisizione di Inhibrx da parte di Sanofi le permette di giocare in unmercato in crescita e ampio -- Market TalkEU:SANSanofi
01/23/20243:56AMDow Jones NewsUPDATE: Sanofi va acquérir Inhibrx pour un montant maximum de 2,2 milliards de dollarsEU:SANSanofi
01/23/20243:51AMDow Jones NewsUPDATE: Sanofi va acquérir Inhibrx pour un montant maximum de 2,2 milliards de dollarsEU:SANSanofi
01/23/20242:25AMDow Jones NewsSanofi va acquérir Inhibrx pour un montant maximum de 2,2 milliards de dollarsEU:SANSanofi
01/23/20242:20AMDow Jones NewsSanofi va acquérir Inhibrx pour un montant maximum de 2,2 milliards de dollarsEU:SANSanofi
01/23/20241:30AMGlobeNewswire Inc.Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipelineEU:SANSanofi
01/23/20241:30AMGlobeNewswire Inc.Communiqué de presse : Sanofi va acquérir Inhibrx, Inc. et ajouter à son portefeuille Maladies rares un actif pour le traitement du déficit en alpha-1-antitrypsine, potentiellement le meilleur de sa classe pharmacothérapeutiqueEU:SANSanofi
01/23/20241:30AMGlobeNewswire Inc.Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipelineEU:SANSanofi
01/17/20244:57PMGlobeNewswire Inc.Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2023EU:SANSanofi
01/17/20244:57PMGlobeNewswire Inc.Sanofi: Information concerning the total number of voting rights and shares - December 2023EU:SANSanofi
01/16/20245:08AMDow Jones NewsECHO BOURSE: Sanofi relevé de "neutre" à "acheter" par UBSEU:SANSanofi
01/09/20242:14AMDow Jones NewsSanofi Names Brian Foard Head of Specialty-Care UnitEU:SANSanofi
 Showing the most relevant articles for your search:EU:SAN

Your Recent History

USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
GRST
Ethema Health (PK)
USOTC
AABB
Asia Broadband (PK)
COIN
BTCUSD
Bitcoin
USOTC
SPZI
Spooz (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
FFIE
Faraday Future Intellige...
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
SMCE
SMC Entertainment (PK)
NASDAQ
COOP
Mr Cooper
USOTC
EMGE
Emergent Health (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
BIEL
Bioelectronics (PK)
USOTC
BLEG
Branded Legacy (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved